登录 | 注册    关注公众号  
微信公众号
搜索
 > 【COMP】

COMP信息

英文名称:Sodium channel protein type VIII alpha subunit
中文名称:VIII型钠通道蛋白α亚基
靶点别称:MYOCL2,Sodium Channel, Voltage Gated, Type VIII, Alpha Subunit,Sodium Channel, Voltage Gated, Type VIII Alpha Subunit,NAV1.6 Voltage-Gated Sodium Channel,Sodium channel protein type 8 subunit alpha,Sodium channel protein type VIII subunit alpha,MED,SCN8A,Sodium Voltage-Gated Channel Alpha Subunit 8,Voltage-Gated Sodium Channel Subunit Alpha Nav1.6,Sodium Channel, Voltage Gated, Type VIII, Alpha Polypeptide,Voltage-Gated Sodium Channel Type VIII Alpha Protein,HNa6/Scn8a Voltage-Gated Sodium Chann
上市药物数量:1
临床药物数量:3
最高研发阶段:批准上市

COMP产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
COP-H5220
Human
Human COMP / TSP5 Protein, His Tag
ACRO质量管理体系
 
评论(0)
 

COMP 分子别名

COMP,TSP5,EDM1,EPD1,MED,PSACH,THBS5

COMP 分子背景

Cartilage oligomeric matrix protein (COMP) is also known as Thrombospondin-5 (TSP5), EDM1, EPD1, MED, PSACH, THBS5, which belongs to the thrombospondin family. COMP / TSP5 contains 4 EGF-like domains, 1 TSP C-terminal (TSPC) domain, 8 TSP type-3 repeats. Abundantly expressed in the chondrocyte extracellular matrix, and is also found in bone, tendon, ligament and synovium and blood vessels. COMP may play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. COMP can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. Thrombospondin-5 could play a role in the pathogenesis of osteoarthritis. COMP is a marker of cartilage turnover.

COMP 前沿进展

COMP上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Pirmenol Hydrochloride 盐酸吡美诺 CI-845 批准上市 辉瑞制药有限公司, 大日本住友 Pimavar, Pimenol Japan 心律失常 null 1994-01-01 心律失常 详情

COMP临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
PRAX-562 PRAX-562 临床二期 Praxis Precision Medicines 脑疾病, 癫痫 详情
PRAX-330 GS-458967; GS-967; PRAX-330 临床一期 Praxis Precision Medicines Inc 癫痫 详情
XEN-901 NBI-921352; XEN-901 临床二期 Xenon Pharma 癫痫发作, 癫痫部分性发作, 脑疾病, 癫痫 详情

消息提示

请输入您的联系方式,再点击提交!

确定